BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
Kidney
,
DNA fingerprint
,
Doxorubicin
,
rs6983267
,
EGFR
,
Metabolism of xenobiotics
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
PD173074
(compound)
Summary
General Info
Genetic Markers
Most Correlated Genes
RBP4
SERPINA3
GPM6A
XIST
CEACAM6
Explore Genetic Markers Results
Pathway Enrichment
Most Correlated Biogroups
organic cyclic compound binding
heterocyclic compound binding
regulation of nitrogen compound metabolic process
organic cyclic compound metabolic process
nucleoplasm
Explore Pathway Enrichment Results
Curated Studies
Most Correlated Studies
FGFR2 signaling in MCF7 breast cancer cells
Bladder cancer MGH-U3 cells with FGFR3 Y375C mutation and TAK1 siRNA treated with PD 173074
ESC-like cell populations derived from pluripotent epiblast stem cells
L1000 CMAP - Breast cancer MCF7 cells treated with small molecule perturbagens (3 of 4)
L1000 CMAP - Breast cancer MCF7 cells treated with small molecule perturbagens (2 of 4)
Explore Curated Studies Results
Literature
Most Relevant Literature
The FGFR inhibitor PD173074 binds to the C-terminus of oncofetal HMGA2 and modulates its DNA-binding…
The FGF receptor inhibitor PD173074 modulates Lefty expression in human induced pluripotent stem cel…
NMR backbone assignments of the tyrosine kinase domain of human fibroblast growth factor receptor 3 …
FGFR1 selective inhibitor PD173074 can reduce proliferation and induce apoptosis of nasopharyngeal c…
Targeted PARP Inhibition Combined with FGFR1 Blockade is Synthetically Lethal to Malignant Cells in …
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
BIBF 1120 as Second Line Treatment for Small Cell Lung Cancer
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ